Pfizer, Inc. (PFE) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $26.77 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: top-12 products (65.0%).
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines through its Biopharma segment globally. Revenue is generated from sales in developed and emerging markets; 41% of 2025 revenues were international, with 21% from... Read more
Sell if holding. Analyst target reached at $26.77 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: top-12 products (65.0%). Chart setup: RSI 48 mid-range, Bollinger mid-band. Score 5.2/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news boost analyst 0.40, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 5d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProducttop-12 products65%10-K Item 1A: 'We recorded revenues of more than $1 billion for each of 12 products that collectively accounted for 65% of Total revenues in 2025.'
- LOWProductEliquis13%10-K Item 1A: 'For example, Eliquis accounted for 13% of Total revenues in 2025.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers
Revenue shrinking — -1.2% YoY. Growth thesis broken unless recovery story develops.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $26.77 — A.R:R is negative (-0.5) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: top-12 products (65.0%). Chart setup: RSI 48 mid-range, Bollinger mid-band. Prior stop was $25.66. Score 5.2/10, moderate confidence.
Take-profit target: $28.18 (+5.2% upside). Prior stop was $25.66. Stop-loss: $25.66.
Concentration risk — Product: top-12 products (65.0%); Analyst target reached - limited upside remaining; Earnings in 5 days (event risk).
Pfizer, Inc. trades at a P/E of 19.3 (forward 9.3). TrendMatrix value score: 7.0/10. Verdict: Sell.
35 analysts cover PFE with a consensus score of 3.5/5. Average price target: $29.
What does Pfizer, Inc. do?Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines...
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines through its Biopharma segment globally. Revenue is generated from sales in developed and emerging markets; 41% of 2025 revenues were international, with 21% from Europe and 12% from China/Japan/Asia Pacific. The company is scaling AI across R&D and commercial operations and recently acquired Metsera (obesity) and Seagen (oncology).